CA2537088A1 - Antagonistes selectifs vis-a-vis du courant sodique persistant pour le traitement des troubles neurologiques et de la douleur - Google Patents

Info

Publication number

CA2537088A1

CA2537088A1 CA002537088A CA2537088A CA2537088A1 CA 2537088 A1 CA2537088 A1 CA 2537088A1 CA 002537088 A CA002537088 A CA 002537088A CA 2537088 A CA2537088 A CA 2537088A CA 2537088 A1 CA2537088 A1 CA 2537088A1

Authority

CA

Canada

Prior art keywords

alkyl

antagonist

sodium current

persistent

hydrogen

Prior art date

2003-08-29

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Links

• Espacenet
• Global Dossier
• CIPO
• Discuss

• 239000011734 sodium Substances 0.000 title claims abstract description 428
• 230000002085 persistent effect Effects 0.000 title claims abstract description 368
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 title claims abstract description 362
• 229910052708 sodium Inorganic materials 0.000 title claims abstract description 361
• 208000002193 Pain Diseases 0.000 title claims abstract description 198
• 208000012902 Nervous system disease Diseases 0.000 title claims abstract description 17
• 230000036407 pain Effects 0.000 title claims description 119
• 239000005557 antagonist Substances 0.000 title claims description 118
• 208000025966 Neurological disease Diseases 0.000 title abstract description 7
• 150000001875 compounds Chemical class 0.000 claims abstract description 141
• 230000001052 transient effect Effects 0.000 claims abstract description 83
• 208000000094 Chronic Pain Diseases 0.000 claims abstract description 75
• 239000003814 drug Substances 0.000 claims abstract description 33
• 241000124008 Mammalia Species 0.000 claims abstract description 29
• 239000003195 sodium channel blocking agent Substances 0.000 claims abstract description 29
• 229940089973 Sodium channel antagonist Drugs 0.000 claims abstract description 21
• 238000000034 method Methods 0.000 claims description 179
• MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 113
• 239000000203 mixture Substances 0.000 claims description 91
• 125000003118 aryl group Chemical group 0.000 claims description 88
• 229910052739 hydrogen Inorganic materials 0.000 claims description 83
• 239000001257 hydrogen Substances 0.000 claims description 83
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 68
• 230000001594 aberrant effect Effects 0.000 claims description 63
• 125000003710 aryl alkyl group Chemical group 0.000 claims description 58
• 229910052736 halogen Inorganic materials 0.000 claims description 55
• 150000002367 halogens Chemical class 0.000 claims description 47
• 208000004296 neuralgia Diseases 0.000 claims description 45
• 238000011282 treatment Methods 0.000 claims description 44
• 208000021722 neuropathic pain Diseases 0.000 claims description 43
• 125000000217 alkyl group Chemical group 0.000 claims description 41
• 208000028867 ischemia Diseases 0.000 claims description 41
• 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 39
• JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims description 37
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 36
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 36
• 206010021143 Hypoxia Diseases 0.000 claims description 35
• 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 35
• 208000035475 disorder Diseases 0.000 claims description 33
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 32
• 206010015037 epilepsy Diseases 0.000 claims description 31
• 241000282414 Homo sapiens Species 0.000 claims description 30
• 230000007954 hypoxia Effects 0.000 claims description 28
• 230000006378 damage Effects 0.000 claims description 27
• 208000014674 injury Diseases 0.000 claims description 27
• 201000001119 neuropathy Diseases 0.000 claims description 27
• 230000007823 neuropathy Effects 0.000 claims description 27
• 150000003839 salts Chemical class 0.000 claims description 26
• -1 hydroxy, amino Chemical group 0.000 claims description 22
• 125000001153 fluoro group Chemical group F* 0.000 claims description 21
• 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 21
• 208000027418 Wounds and injury Diseases 0.000 claims description 20
• 150000001408 amides Chemical class 0.000 claims description 20
• 206010028980 Neoplasm Diseases 0.000 claims description 19
• 230000000626 neurodegenerative effect Effects 0.000 claims description 19
• 229910052760 oxygen Inorganic materials 0.000 claims description 19
• 150000002148 esters Chemical class 0.000 claims description 18
• 229940125904 compound 1 Drugs 0.000 claims description 17
• 208000033808 peripheral neuropathy Diseases 0.000 claims description 17
• 230000001684 chronic effect Effects 0.000 claims description 14
• 230000000302 ischemic effect Effects 0.000 claims description 14
• 208000002780 macular degeneration Diseases 0.000 claims description 13
• 230000000926 neurological effect Effects 0.000 claims description 13
• 206010019233 Headaches Diseases 0.000 claims description 12
• 208000017442 Retinal disease Diseases 0.000 claims description 12
• 231100000869 headache Toxicity 0.000 claims description 12
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 12
• 206010012689 Diabetic retinopathy Diseases 0.000 claims description 11
• 206010061218 Inflammation Diseases 0.000 claims description 11
• 208000016285 Movement disease Diseases 0.000 claims description 11
• 208000027866 inflammatory disease Diseases 0.000 claims description 11
• 230000004054 inflammatory process Effects 0.000 claims description 11
• 208000012514 Cumulative Trauma disease Diseases 0.000 claims description 10
• 125000001544 thienyl group Chemical group 0.000 claims description 10
• 206010012289 Dementia Diseases 0.000 claims description 9
• 230000003542 behavioural effect Effects 0.000 claims description 9
• 208000011580 syndromic disease Diseases 0.000 claims description 9
• 208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims description 8
• 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 8
• 208000001640 Fibromyalgia Diseases 0.000 claims description 8
• 206010064930 age-related macular degeneration Diseases 0.000 claims description 8
• 208000015181 infectious disease Diseases 0.000 claims description 8
• 208000009935 visceral pain Diseases 0.000 claims description 8
• 208000001387 Causalgia Diseases 0.000 claims description 7
• 201000011510 cancer Diseases 0.000 claims description 7
• 229910052717 sulfur Inorganic materials 0.000 claims description 7
• 208000010412 Glaucoma Diseases 0.000 claims description 6
• 206010036105 Polyneuropathy Diseases 0.000 claims description 6
• 206010038923 Retinopathy Diseases 0.000 claims description 6
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
• 230000007824 polyneuropathy Effects 0.000 claims description 6
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
• 208000023275 Autoimmune disease Diseases 0.000 claims description 5
• 125000000623 heterocyclic group Chemical group 0.000 claims description 5
• 201000005518 mononeuropathy Diseases 0.000 claims description 5
• 208000016192 Demyelinating disease Diseases 0.000 claims description 4
• 201000007737 Retinal degeneration Diseases 0.000 claims description 4
• 125000002837 carbocyclic group Chemical group 0.000 claims description 4
• 208000018631 connective tissue disease Diseases 0.000 claims description 4
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
• HGJZILLZLLIURH-UHFFFAOYSA-N 2-(1-benzyl-2h-pyridin-4-yl)-5-phenyl-1,3,4-oxadiazole Chemical group C=1C=CC=CC=1CN(C=C1)CC=C1C(O1)=NN=C1C1=CC=CC=C1 HGJZILLZLLIURH-UHFFFAOYSA-N 0.000 claims description 3
• FVBKCGDESMAHPJ-UHFFFAOYSA-N 3-methyl-6-propan-2-yl-2-[[4-[(4-propoxyphenyl)methylideneamino]phenyl]methylidene]cyclohexan-1-one Chemical group C1=CC(OCCC)=CC=C1C=NC(C=C1)=CC=C1C=C1C(=O)C(C(C)C)CCC1C FVBKCGDESMAHPJ-UHFFFAOYSA-N 0.000 claims description 3
• 208000035719 Maculopathy Diseases 0.000 claims description 3
• 206010049816 Muscle tightness Diseases 0.000 claims description 3
• 206010061323 Optic neuropathy Diseases 0.000 claims description 3
• 229940125782 compound 2 Drugs 0.000 claims description 3
• 229940126214 compound 3 Drugs 0.000 claims description 3
• ADYXWQBCSLCTGH-UHFFFAOYSA-N n-(4-phenylbutyl)thiophene-2-carboxamide Chemical group C=1C=CSC=1C(=O)NCCCCC1=CC=CC=C1 ADYXWQBCSLCTGH-UHFFFAOYSA-N 0.000 claims description 3
• 208000020911 optic nerve disease Diseases 0.000 claims description 3
• KEPNUSGYBWUVGM-UHFFFAOYSA-N phenacyl 3-[(2,2,2-trifluoroacetyl)amino]benzoate Chemical group FC(F)(F)C(=O)NC1=CC=CC(C(=O)OCC(=O)C=2C=CC=CC=2)=C1 KEPNUSGYBWUVGM-UHFFFAOYSA-N 0.000 claims description 3
• 230000004258 retinal degeneration Effects 0.000 claims description 3
• 206010057430 Retinal injury Diseases 0.000 claims description 2
• 208000016624 Retinal neoplasm Diseases 0.000 claims description 2
• 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims description 2
• 230000002917 arthritic effect Effects 0.000 claims description 2
• 208000018360 neuromuscular disease Diseases 0.000 claims description 2
• 150000002431 hydrogen Chemical group 0.000 claims 40
• 125000005843 halogen group Chemical group 0.000 claims 8
• 101000869592 Daucus carota Major allergen Dau c 1 Proteins 0.000 claims 2
• 101000650136 Homo sapiens WAS/WASL-interacting protein family member 3 Proteins 0.000 claims 2
• 102100027539 WAS/WASL-interacting protein family member 3 Human genes 0.000 claims 2
• 230000002980 postoperative effect Effects 0.000 claims 1
• 208000024725 retina neoplasm Diseases 0.000 claims 1
• 201000008933 retinal cancer Diseases 0.000 claims 1
• 238000013268 sustained release Methods 0.000 claims 1
• 239000012730 sustained-release form Substances 0.000 claims 1
• 108010052164 Sodium Channels Proteins 0.000 description 97
• 210000004027 cell Anatomy 0.000 description 96
• 102000018674 Sodium Channels Human genes 0.000 description 94
• 230000000694 effects Effects 0.000 description 63
• 210000002569 neuron Anatomy 0.000 description 51
• 208000024891 symptom Diseases 0.000 description 49
• 230000028161 membrane depolarization Effects 0.000 description 46
• 108091006146 Channels Proteins 0.000 description 44
• 229910001415 sodium ion Inorganic materials 0.000 description 44
• 238000002560 therapeutic procedure Methods 0.000 description 43
• 206010010904 Convulsion Diseases 0.000 description 41
• 238000003556 assay Methods 0.000 description 41
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 41
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 38
• 230000004044 response Effects 0.000 description 37
• 201000010099 disease Diseases 0.000 description 35
• 241000700159 Rattus Species 0.000 description 33
• 239000000243 solution Substances 0.000 description 33
• 230000003834 intracellular effect Effects 0.000 description 30
• 241001465754 Metazoa Species 0.000 description 29
• 238000012360 testing method Methods 0.000 description 28
• 230000001419 dependent effect Effects 0.000 description 26
• 201000006417 multiple sclerosis Diseases 0.000 description 25
• 230000009467 reduction Effects 0.000 description 25
• 210000003050 axon Anatomy 0.000 description 23
• 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 description 22
• 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 description 22
• 229940079593 drug Drugs 0.000 description 22
• 230000001965 increasing effect Effects 0.000 description 22
• 210000001519 tissue Anatomy 0.000 description 22
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 21
• 210000003169 central nervous system Anatomy 0.000 description 21
• 230000006870 function Effects 0.000 description 21
• 208000004454 Hyperalgesia Diseases 0.000 description 20
• 210000004556 brain Anatomy 0.000 description 20
• 235000002639 sodium chloride Nutrition 0.000 description 20
• 238000006243 chemical reaction Methods 0.000 description 19
• 230000016273 neuron death Effects 0.000 description 19
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
• 201000006474 Brain Ischemia Diseases 0.000 description 16
• 206010008120 Cerebral ischaemia Diseases 0.000 description 16
• 241000699670 Mus sp. Species 0.000 description 16
• 206010008118 cerebral infarction Diseases 0.000 description 16
• 239000012528 membrane Substances 0.000 description 16
• 210000005036 nerve Anatomy 0.000 description 16
• 239000008194 pharmaceutical composition Substances 0.000 description 16
• 206010033799 Paralysis Diseases 0.000 description 15
• 239000001301 oxygen Substances 0.000 description 15
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 14
• 238000007792 addition Methods 0.000 description 14
• 230000015572 biosynthetic process Effects 0.000 description 14
• 210000002683 foot Anatomy 0.000 description 14
• 230000004770 neurodegeneration Effects 0.000 description 14
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 13
• 230000000670 limiting effect Effects 0.000 description 13
• CPRRHERYRRXBRZ-SRVKXCTJSA-N methyl n-[(2s)-1-[[(2s)-1-hydroxy-3-[(3s)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamate Chemical compound COC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CO)C[C@@H]1CCNC1=O CPRRHERYRRXBRZ-SRVKXCTJSA-N 0.000 description 13
• 230000002093 peripheral effect Effects 0.000 description 13
• 206010053552 allodynia Diseases 0.000 description 12
• 238000010171 animal model Methods 0.000 description 12
• 239000000872 buffer Substances 0.000 description 12
• 238000002474 experimental method Methods 0.000 description 12
• 150000002500 ions Chemical class 0.000 description 12
• 230000003961 neuronal insult Effects 0.000 description 12
• 238000001356 surgical procedure Methods 0.000 description 12
• 230000002207 retinal effect Effects 0.000 description 11
• 102000004310 Ion Channels Human genes 0.000 description 10
• 108090000862 Ion Channels Proteins 0.000 description 10
• 230000002159 abnormal effect Effects 0.000 description 10
• 230000036982 action potential Effects 0.000 description 10
• 230000000903 blocking effect Effects 0.000 description 10
• 239000011575 calcium Substances 0.000 description 10
• ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 10
• 206010012601 diabetes mellitus Diseases 0.000 description 10
• 210000001508 eye Anatomy 0.000 description 10
• 238000002866 fluorescence resonance energy transfer Methods 0.000 description 10
• 230000005764 inhibitory process Effects 0.000 description 10
• 239000007924 injection Substances 0.000 description 10
• 238000002347 injection Methods 0.000 description 10
• 210000003205 muscle Anatomy 0.000 description 10
• 230000001537 neural effect Effects 0.000 description 10
• 208000015122 neurodegenerative disease Diseases 0.000 description 10
• 230000002981 neuropathic effect Effects 0.000 description 10
• 210000001328 optic nerve Anatomy 0.000 description 10
• 230000008569 process Effects 0.000 description 10
• 230000002829 reductive effect Effects 0.000 description 10
• 208000002381 Brain Hypoxia Diseases 0.000 description 9
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
• 230000004913 activation Effects 0.000 description 9
• 230000000202 analgesic effect Effects 0.000 description 9
• 230000017531 blood circulation Effects 0.000 description 9
• 230000004048 modification Effects 0.000 description 9
• 238000012986 modification Methods 0.000 description 9
• 239000002773 nucleotide Substances 0.000 description 9
• 208000021090 palsy Diseases 0.000 description 9
• 210000001428 peripheral nervous system Anatomy 0.000 description 9
• 239000000523 sample Substances 0.000 description 9
• 230000001953 sensory effect Effects 0.000 description 9
• 238000003786 synthesis reaction Methods 0.000 description 9
• GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 9
• 229960002372 tetracaine Drugs 0.000 description 9
• 102000040650 (ribonucleotides)n+m Human genes 0.000 description 8
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 8
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 8
• 206010065390 Inflammatory pain Diseases 0.000 description 8
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 8
• 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 8
• 230000001154 acute effect Effects 0.000 description 8
• 229910052791 calcium Inorganic materials 0.000 description 8
• 230000007423 decrease Effects 0.000 description 8
• 239000000975 dye Substances 0.000 description 8
• 230000009368 gene silencing by RNA Effects 0.000 description 8
• 229930195712 glutamate Natural products 0.000 description 8
• 230000033001 locomotion Effects 0.000 description 8
• 125000003729 nucleotide group Chemical group 0.000 description 8
• 210000000056 organ Anatomy 0.000 description 8
• 108090000623 proteins and genes Proteins 0.000 description 8
• 239000011541 reaction mixture Substances 0.000 description 8
• 230000000284 resting effect Effects 0.000 description 8
• 238000012216 screening Methods 0.000 description 8
• 230000008733 trauma Effects 0.000 description 8
• 208000028389 Nerve injury Diseases 0.000 description 7
• 208000004983 Phantom Limb Diseases 0.000 description 7
• 206010056238 Phantom pain Diseases 0.000 description 7
• 208000006011 Stroke Diseases 0.000 description 7
• 208000029977 White Dot Syndromes Diseases 0.000 description 7
• 230000006399 behavior Effects 0.000 description 7
• YKYOUMDCQGMQQO-UHFFFAOYSA-L cadmium dichloride Chemical compound Cl[Cd]Cl YKYOUMDCQGMQQO-UHFFFAOYSA-L 0.000 description 7
• 239000003795 chemical substances by application Substances 0.000 description 7
• 238000002512 chemotherapy Methods 0.000 description 7
• 238000010304 firing Methods 0.000 description 7
• 238000009472 formulation Methods 0.000 description 7
• 210000002216 heart Anatomy 0.000 description 7
• 210000000548 hind-foot Anatomy 0.000 description 7
• 230000001146 hypoxic effect Effects 0.000 description 7
• 230000003902 lesion Effects 0.000 description 7
• 230000008764 nerve damage Effects 0.000 description 7
• 230000006764 neuronal dysfunction Effects 0.000 description 7
• 230000008062 neuronal firing Effects 0.000 description 7
• 229910052757 nitrogen Inorganic materials 0.000 description 7
• 235000021251 pulses Nutrition 0.000 description 7
• 208000004644 retinal vein occlusion Diseases 0.000 description 7
• 230000002441 reversible effect Effects 0.000 description 7
• 210000001032 spinal nerve Anatomy 0.000 description 7
• 230000002459 sustained effect Effects 0.000 description 7
• 208000024827 Alzheimer disease Diseases 0.000 description 6
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
• 239000012981 Hank's balanced salt solution Substances 0.000 description 6
• 241000699666 Mus <mouse, genus> Species 0.000 description 6
• KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
• FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 description 6
• 235000011054 acetic acid Nutrition 0.000 description 6
• 239000002253 acid Substances 0.000 description 6
• 239000004480 active ingredient Substances 0.000 description 6
• 238000004458 analytical method Methods 0.000 description 6
• 239000001961 anticonvulsive agent Substances 0.000 description 6
• 239000002775 capsule Substances 0.000 description 6
• 230000034994 death Effects 0.000 description 6
• 230000003247 decreasing effect Effects 0.000 description 6
• 230000002939 deleterious effect Effects 0.000 description 6
• 230000000415 inactivating effect Effects 0.000 description 6
• 230000004941 influx Effects 0.000 description 6
• 239000003112 inhibitor Substances 0.000 description 6
• 230000007246 mechanism Effects 0.000 description 6
• 230000035772 mutation Effects 0.000 description 6
• 150000007523 nucleic acids Chemical class 0.000 description 6
• 230000002035 prolonged effect Effects 0.000 description 6
• 206010039073 rheumatoid arthritis Diseases 0.000 description 6
• 229960004181 riluzole Drugs 0.000 description 6
• 210000000278 spinal cord Anatomy 0.000 description 6
• 238000010186 staining Methods 0.000 description 6
• 239000000126 substance Substances 0.000 description 6
• 125000001424 substituent group Chemical group 0.000 description 6
• 230000001225 therapeutic effect Effects 0.000 description 6
• 206010044652 trigeminal neuralgia Diseases 0.000 description 6
• 239000003981 vehicle Substances 0.000 description 6
• 206010001497 Agitation Diseases 0.000 description 5
• 208000024255 Audiogenic seizures Diseases 0.000 description 5
• 208000000412 Avitaminosis Diseases 0.000 description 5
• 241000282693 Cercopithecidae Species 0.000 description 5
• 208000035154 Hyperesthesia Diseases 0.000 description 5
• 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 5
• 206010036376 Postherpetic Neuralgia Diseases 0.000 description 5
• 206010047627 Vitamin deficiencies Diseases 0.000 description 5
• 230000005856 abnormality Effects 0.000 description 5
• 125000003545 alkoxy group Chemical group 0.000 description 5
• 125000002877 alkyl aryl group Chemical group 0.000 description 5
• 206010003119 arrhythmia Diseases 0.000 description 5
• 230000003376 axonal effect Effects 0.000 description 5
• 230000008901 benefit Effects 0.000 description 5
• 230000036770 blood supply Effects 0.000 description 5
• 102000006889 calcium:sodium antiporter activity proteins Human genes 0.000 description 5
• 108040000797 calcium:sodium antiporter activity proteins Proteins 0.000 description 5
• 229910052799 carbon Inorganic materials 0.000 description 5
• 210000003618 cortical neuron Anatomy 0.000 description 5
• 229960000956 coumarin Drugs 0.000 description 5
• 235000001671 coumarin Nutrition 0.000 description 5
• 125000004093 cyano group Chemical group *C#N 0.000 description 5
• 230000003111 delayed effect Effects 0.000 description 5
• 210000004209 hair Anatomy 0.000 description 5
• 230000002757 inflammatory effect Effects 0.000 description 5
• 238000007912 intraperitoneal administration Methods 0.000 description 5
• 208000002551 irritable bowel syndrome Diseases 0.000 description 5
• 208000031225 myocardial ischemia Diseases 0.000 description 5
• 230000001575 pathological effect Effects 0.000 description 5
• 210000000578 peripheral nerve Anatomy 0.000 description 5
• 239000012071 phase Substances 0.000 description 5
• 230000002062 proliferating effect Effects 0.000 description 5
• 230000002336 repolarization Effects 0.000 description 5
• 210000001525 retina Anatomy 0.000 description 5
• 238000011808 rodent model Methods 0.000 description 5
• 210000003497 sciatic nerve Anatomy 0.000 description 5
• 230000035945 sensitivity Effects 0.000 description 5
• 230000002269 spontaneous effect Effects 0.000 description 5
• 230000009885 systemic effect Effects 0.000 description 5
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
• 210000000707 wrist Anatomy 0.000 description 5
• 208000030507 AIDS Diseases 0.000 description 4
• 108091023037 Aptamer Proteins 0.000 description 4
• 241000282472 Canis lupus familiaris Species 0.000 description 4
• 208000035473 Communicable disease Diseases 0.000 description 4
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
• 208000023105 Huntington disease Diseases 0.000 description 4
• 206010065952 Hyperpathia Diseases 0.000 description 4
• 208000019695 Migraine disease Diseases 0.000 description 4
• 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 4
• 208000001294 Nociceptive Pain Diseases 0.000 description 4
• 208000018737 Parkinson disease Diseases 0.000 description 4
• 208000004550 Postoperative Pain Diseases 0.000 description 4
• 206010036618 Premenstrual syndrome Diseases 0.000 description 4
• 230000002411 adverse Effects 0.000 description 4
• VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 4
• 230000003042 antagnostic effect Effects 0.000 description 4
• 239000000730 antalgic agent Substances 0.000 description 4
• 230000006907 apoptotic process Effects 0.000 description 4
• 210000004204 blood vessel Anatomy 0.000 description 4
• 210000005252 bulbus oculi Anatomy 0.000 description 4
• 125000004432 carbon atom Chemical group C* 0.000 description 4
• 210000000170 cell membrane Anatomy 0.000 description 4
• 230000036461 convulsion Effects 0.000 description 4
• 238000011161 development Methods 0.000 description 4
• 230000018109 developmental process Effects 0.000 description 4
• 239000003937 drug carrier Substances 0.000 description 4
• 230000003492 excitotoxic effect Effects 0.000 description 4
• 238000013265 extended release Methods 0.000 description 4
• 230000002779 inactivation Effects 0.000 description 4
• 230000000977 initiatory effect Effects 0.000 description 4
• PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 4
• 238000005259 measurement Methods 0.000 description 4
• 230000001404 mediated effect Effects 0.000 description 4
• 206010027599 migraine Diseases 0.000 description 4
• 238000002156 mixing Methods 0.000 description 4
• 210000000653 nervous system Anatomy 0.000 description 4
• 230000000324 neuroprotective effect Effects 0.000 description 4
• 102000039446 nucleic acids Human genes 0.000 description 4
• 108020004707 nucleic acids Proteins 0.000 description 4
• 230000003287 optical effect Effects 0.000 description 4
• 230000000750 progressive effect Effects 0.000 description 4
• 210000001567 regular cardiac muscle cell of ventricle Anatomy 0.000 description 4
• 210000003594 spinal ganglia Anatomy 0.000 description 4
• 230000000638 stimulation Effects 0.000 description 4
• 239000003053 toxin Substances 0.000 description 4
• 231100000765 toxin Toxicity 0.000 description 4
• 108700012359 toxins Proteins 0.000 description 4
• 238000011830 transgenic mouse model Methods 0.000 description 4
• 230000000472 traumatic effect Effects 0.000 description 4
• 230000003827 upregulation Effects 0.000 description 4
• 230000002792 vascular Effects 0.000 description 4
• VJYNRXFXHKIGLT-UHFFFAOYSA-N 5-[3-(1,3-diethyl-4,6-dioxo-2-sulfanylidene-1,3-diazinan-5-yl)prop-2-enylidene]-1,3-diethyl-2-sulfanylidene-1,3-diazinane-4,6-dione Chemical compound O=C1N(CC)C(=S)N(CC)C(=O)C1C=CC=C1C(=O)N(CC)C(=S)N(CC)C1=O VJYNRXFXHKIGLT-UHFFFAOYSA-N 0.000 description 3
• 208000007848 Alcoholism Diseases 0.000 description 3
• 206010003694 Atrophy Diseases 0.000 description 3
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
• 206010064147 Gastrointestinal inflammation Diseases 0.000 description 3
• 241000699694 Gerbillinae Species 0.000 description 3
• 201000005569 Gout Diseases 0.000 description 3
• 206010018634 Gouty Arthritis Diseases 0.000 description 3
• 208000035895 Guillain-Barré syndrome Diseases 0.000 description 3
• 208000031886 HIV Infections Diseases 0.000 description 3
• 208000037357 HIV infectious disease Diseases 0.000 description 3
• 208000010496 Heart Arrest Diseases 0.000 description 3
• 101000631760 Homo sapiens Sodium channel protein type 1 subunit alpha Proteins 0.000 description 3
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
• NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 3
• 208000001344 Macular Edema Diseases 0.000 description 3
• 206010049567 Miller Fisher syndrome Diseases 0.000 description 3
• 208000000112 Myalgia Diseases 0.000 description 3
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
• 108010021487 Nitric Oxide Synthase Proteins 0.000 description 3
• 206010033892 Paraplegia Diseases 0.000 description 3
• CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 3
• 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 3
• 201000007527 Retinal artery occlusion Diseases 0.000 description 3
• 208000007014 Retinitis pigmentosa Diseases 0.000 description 3
• 241000283984 Rodentia Species 0.000 description 3
• 208000008765 Sciatica Diseases 0.000 description 3
• PDOCBJADCWMDGL-UHFFFAOYSA-N Sipatrigine Chemical compound C1CN(C)CCN1C1=NC=C(C=2C(=C(Cl)C=C(Cl)C=2)Cl)C(N)=N1 PDOCBJADCWMDGL-UHFFFAOYSA-N 0.000 description 3
• 229940127505 Sodium Channel Antagonists Drugs 0.000 description 3
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
• 102000001794 Sodium-Calcium Exchanger Human genes 0.000 description 3
• 108010040240 Sodium-Calcium Exchanger Proteins 0.000 description 3
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
• 239000000370 acceptor Substances 0.000 description 3
• 230000003213 activating effect Effects 0.000 description 3
• 208000005298 acute pain Diseases 0.000 description 3
• 201000007930 alcohol dependence Diseases 0.000 description 3
• 125000003342 alkenyl group Chemical group 0.000 description 3
• 125000000304 alkynyl group Chemical group 0.000 description 3
• 150000001412 amines Chemical class 0.000 description 3
• 230000000692 anti-sense effect Effects 0.000 description 3
• 206010003246 arthritis Diseases 0.000 description 3
• 208000006673 asthma Diseases 0.000 description 3
• 230000037444 atrophy Effects 0.000 description 3
• 239000005441 aurora Substances 0.000 description 3
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
• 230000037396 body weight Effects 0.000 description 3
• 230000000747 cardiac effect Effects 0.000 description 3
• 230000030833 cell death Effects 0.000 description 3
• 230000001413 cellular effect Effects 0.000 description 3
• 201000005667 central retinal vein occlusion Diseases 0.000 description 3
• 230000002490 cerebral effect Effects 0.000 description 3
• 230000008859 change Effects 0.000 description 3
• 101150087654 chrnd gene Proteins 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 238000007906 compression Methods 0.000 description 3
• 230000006835 compression Effects 0.000 description 3
• 210000000795 conjunctiva Anatomy 0.000 description 3
• 238000011461 current therapy Methods 0.000 description 3
• 125000004122 cyclic group Chemical group 0.000 description 3
• 230000007850 degeneration Effects 0.000 description 3
• 230000002999 depolarising effect Effects 0.000 description 3
• 230000001627 detrimental effect Effects 0.000 description 3
• AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 3
• 229960003529 diazepam Drugs 0.000 description 3
• 238000009792 diffusion process Methods 0.000 description 3
• 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 3
• 230000003292 diminished effect Effects 0.000 description 3
• 238000009826 distribution Methods 0.000 description 3
• 230000008030 elimination Effects 0.000 description 3
• 238000003379 elimination reaction Methods 0.000 description 3
• 239000012530 fluid Substances 0.000 description 3
• 230000004907 flux Effects 0.000 description 3
• 210000004247 hand Anatomy 0.000 description 3
• 230000009931 harmful effect Effects 0.000 description 3
• 239000005556 hormone Substances 0.000 description 3
• 229940088597 hormone Drugs 0.000 description 3
• 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 3
• 125000001183 hydrocarbyl group Chemical group 0.000 description 3
• 239000007943 implant Substances 0.000 description 3
• 230000008676 import Effects 0.000 description 3
• 230000001976 improved effect Effects 0.000 description 3
• 238000011534 incubation Methods 0.000 description 3
• 230000006698 induction Effects 0.000 description 3
• 230000002401 inhibitory effect Effects 0.000 description 3
• 229960001848 lamotrigine Drugs 0.000 description 3
• 229960004194 lidocaine Drugs 0.000 description 3
• 206010025135 lupus erythematosus Diseases 0.000 description 3
• 239000002609 medium Substances 0.000 description 3
• 239000007758 minimum essential medium Substances 0.000 description 3
• 230000004660 morphological change Effects 0.000 description 3
• 210000002161 motor neuron Anatomy 0.000 description 3
• 208000005264 motor neuron disease Diseases 0.000 description 3
• 208000013465 muscle pain Diseases 0.000 description 3
• 230000002107 myocardial effect Effects 0.000 description 3
• 239000002674 ointment Substances 0.000 description 3
• 239000012074 organic phase Substances 0.000 description 3
• 201000008482 osteoarthritis Diseases 0.000 description 3
• 230000001314 paroxysmal effect Effects 0.000 description 3
• 230000007310 pathophysiology Effects 0.000 description 3
• 230000000144 pharmacologic effect Effects 0.000 description 3
• 229960002036 phenytoin Drugs 0.000 description 3
• 230000001144 postural effect Effects 0.000 description 3
• 238000011533 pre-incubation Methods 0.000 description 3
• 230000001105 regulatory effect Effects 0.000 description 3
• 125000006413 ring segment Chemical group 0.000 description 3
• 238000005070 sampling Methods 0.000 description 3
• 210000001044 sensory neuron Anatomy 0.000 description 3
• 229950008911 sipatrigine Drugs 0.000 description 3
• 239000002904 solvent Substances 0.000 description 3
• 238000007920 subcutaneous administration Methods 0.000 description 3
• 239000011593 sulfur Substances 0.000 description 3
• 230000001256 tonic effect Effects 0.000 description 3
• 231100000331 toxic Toxicity 0.000 description 3
• 230000002588 toxic effect Effects 0.000 description 3
• 230000001988 toxicity Effects 0.000 description 3
• 231100000419 toxicity Toxicity 0.000 description 3
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
• 230000001982 uveitic effect Effects 0.000 description 3
• 210000004885 white matter Anatomy 0.000 description 3
• 239000002023 wood Substances 0.000 description 3
• VLPIATFUUWWMKC-SNVBAGLBSA-N (2r)-1-(2,6-dimethylphenoxy)propan-2-amine Chemical compound C[C@@H](N)COC1=C(C)C=CC=C1C VLPIATFUUWWMKC-SNVBAGLBSA-N 0.000 description 2
• BUJAGSGYPOAWEI-SECBINFHSA-N (2r)-2-amino-n-(2,6-dimethylphenyl)propanamide Chemical compound C[C@@H](N)C(=O)NC1=C(C)C=CC=C1C BUJAGSGYPOAWEI-SECBINFHSA-N 0.000 description 2
• PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 2
• GTUBLXPYISHKLW-UHFFFAOYSA-N 2-[(4-aminophenyl)methylidene]-3-methyl-6-propan-2-ylcyclohexan-1-one Chemical compound O=C1C(C(C)C)CCC(C)C1=CC1=CC=C(N)C=C1 GTUBLXPYISHKLW-UHFFFAOYSA-N 0.000 description 2
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
• OWVHKHGMKQTLGA-UHFFFAOYSA-N 3-[(2,2,2-trifluoroacetyl)amino]benzoic acid Chemical compound OC(=O)C1=CC=CC(NC(=O)C(F)(F)F)=C1 OWVHKHGMKQTLGA-UHFFFAOYSA-N 0.000 description 2
• LLKFNPUXQZHIAE-UHFFFAOYSA-N 5-(3-aminopropyl)-8-bromo-3-methyl-2h-pyrazolo[4,3-c]quinolin-4-one Chemical compound O=C1N(CCCN)C2=CC=C(Br)C=C2C2=C1C(C)=NN2 LLKFNPUXQZHIAE-UHFFFAOYSA-N 0.000 description 2
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
• 208000031104 Arterial Occlusive disease Diseases 0.000 description 2
• 208000037157 Azotemia Diseases 0.000 description 2
• 208000008035 Back Pain Diseases 0.000 description 2
• 208000009137 Behcet syndrome Diseases 0.000 description 2
• 208000021657 Birth injury Diseases 0.000 description 2
• 201000004569 Blindness Diseases 0.000 description 2
• BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
• 208000014882 Carotid artery disease Diseases 0.000 description 2
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
• 208000005590 Choroidal Neovascularization Diseases 0.000 description 2
• 206010060823 Choroidal neovascularisation Diseases 0.000 description 2
• 206010053398 Clonic convulsion Diseases 0.000 description 2
• 208000006561 Cluster Headache Diseases 0.000 description 2
• 206010009900 Colitis ulcerative Diseases 0.000 description 2
• 208000011231 Crohn disease Diseases 0.000 description 2
• 206010058202 Cystoid macular oedema Diseases 0.000 description 2
• 206010012305 Demyelination Diseases 0.000 description 2
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
• 206010012688 Diabetic retinal oedema Diseases 0.000 description 2
• MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
• 208000001351 Epiretinal Membrane Diseases 0.000 description 2
• 208000024720 Fabry Disease Diseases 0.000 description 2
• 208000002091 Febrile Seizures Diseases 0.000 description 2
• 241000282326 Felis catus Species 0.000 description 2
• DJBNUMBKLMJRSA-UHFFFAOYSA-N Flecainide Chemical compound FC(F)(F)COC1=CC=C(OCC(F)(F)F)C(C(=O)NCC2NCCCC2)=C1 DJBNUMBKLMJRSA-UHFFFAOYSA-N 0.000 description 2
• 208000007882 Gastritis Diseases 0.000 description 2
• 208000021965 Glossopharyngeal Nerve disease Diseases 0.000 description 2
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
• 239000007995 HEPES buffer Substances 0.000 description 2
• 206010019196 Head injury Diseases 0.000 description 2
• 206010019280 Heart failures Diseases 0.000 description 2
• 206010020772 Hypertension Diseases 0.000 description 2
• 206010061216 Infarction Diseases 0.000 description 2
• 208000003618 Intervertebral Disc Displacement Diseases 0.000 description 2
• 206010050296 Intervertebral disc protrusion Diseases 0.000 description 2
• 208000003456 Juvenile Arthritis Diseases 0.000 description 2
• 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 2
• 206010050219 Lumbar radiculopathy Diseases 0.000 description 2
• TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
• 206010072720 Medication overuse headache Diseases 0.000 description 2
• 208000026072 Motor neurone disease Diseases 0.000 description 2
• 208000001089 Multiple system atrophy Diseases 0.000 description 2
• 241000699660 Mus musculus Species 0.000 description 2
• 208000036572 Myoclonic epilepsy Diseases 0.000 description 2
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
• 102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
• 229910019142 PO4 Inorganic materials 0.000 description 2
• 241001504519 Papio ursinus Species 0.000 description 2
• 208000010886 Peripheral nerve injury Diseases 0.000 description 2
• 208000018262 Peripheral vascular disease Diseases 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• 108010039918 Polylysine Proteins 0.000 description 2
• 208000010366 Postpoliomyelitis syndrome Diseases 0.000 description 2
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
• WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
• 241000288906 Primates Species 0.000 description 2
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
• LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
• 206010064714 Radiation retinopathy Diseases 0.000 description 2
• 208000002367 Retinal Perforations Diseases 0.000 description 2
• 206010038848 Retinal detachment Diseases 0.000 description 2
• 206010039710 Scleroderma Diseases 0.000 description 2
• 206010040744 Sinus headache Diseases 0.000 description 2
• 208000027073 Stargardt disease Diseases 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
• 208000008548 Tension-Type Headache Diseases 0.000 description 2
• 208000007536 Thrombosis Diseases 0.000 description 2
• 206010043994 Tonic convulsion Diseases 0.000 description 2
• 201000005485 Toxoplasmosis Diseases 0.000 description 2
• 206010044565 Tremor Diseases 0.000 description 2
• 201000006704 Ulcerative Colitis Diseases 0.000 description 2
• 206010046851 Uveitis Diseases 0.000 description 2
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
• 241000269370 Xenopus <genus> Species 0.000 description 2
• 150000007513 acids Chemical class 0.000 description 2
• 230000023445 activated T cell autonomous cell death Effects 0.000 description 2
• 208000023564 acute macular neuroretinopathy Diseases 0.000 description 2
• 230000006978 adaptation Effects 0.000 description 2
• 230000004075 alteration Effects 0.000 description 2
• 206010002022 amyloidosis Diseases 0.000 description 2
• 230000036592 analgesia Effects 0.000 description 2
• 229940035676 analgesics Drugs 0.000 description 2
• 238000000540 analysis of variance Methods 0.000 description 2
• 210000003423 ankle Anatomy 0.000 description 2
• 210000002159 anterior chamber Anatomy 0.000 description 2
• 230000000844 anti-bacterial effect Effects 0.000 description 2
• 230000003556 anti-epileptic effect Effects 0.000 description 2
• 229940125681 anticonvulsant agent Drugs 0.000 description 2
• 239000003963 antioxidant agent Substances 0.000 description 2
• 238000013459 approach Methods 0.000 description 2
• 230000006793 arrhythmia Effects 0.000 description 2
• 210000001367 artery Anatomy 0.000 description 2
• 238000002820 assay format Methods 0.000 description 2
• 230000002567 autonomic effect Effects 0.000 description 2
• 239000002585 base Substances 0.000 description 2
• 239000004621 biodegradable polymer Substances 0.000 description 2
• 229920002988 biodegradable polymer Polymers 0.000 description 2
• 230000033228 biological regulation Effects 0.000 description 2
• 230000005540 biological transmission Effects 0.000 description 2
• 210000004369 blood Anatomy 0.000 description 2
• 239000008280 blood Substances 0.000 description 2
• 210000003461 brachial plexus Anatomy 0.000 description 2
• 210000000133 brain stem Anatomy 0.000 description 2
• GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 2
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• 230000001964 calcium overload Effects 0.000 description 2
• YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
• FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 2
• 229960000623 carbamazepine Drugs 0.000 description 2
• 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
• 210000005056 cell body Anatomy 0.000 description 2
• 238000004113 cell culture Methods 0.000 description 2
• 230000003915 cell function Effects 0.000 description 2
• 201000005849 central retinal artery occlusion Diseases 0.000 description 2
• 206010008129 cerebral palsy Diseases 0.000 description 2
• OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
• 208000037976 chronic inflammation Diseases 0.000 description 2
• 208000018912 cluster headache syndrome Diseases 0.000 description 2
• 230000001054 cortical effect Effects 0.000 description 2
• 239000006071 cream Substances 0.000 description 2
• 201000010206 cystoid macular edema Diseases 0.000 description 2
• 239000007933 dermal patch Substances 0.000 description 2
• 238000001514 detection method Methods 0.000 description 2
• 230000009547 development abnormality Effects 0.000 description 2
• 201000011190 diabetic macular edema Diseases 0.000 description 2
• 239000010432 diamond Substances 0.000 description 2
• 239000003085 diluting agent Substances 0.000 description 2
• 239000002552 dosage form Substances 0.000 description 2
• 231100000673 dose–response relationship Toxicity 0.000 description 2
• 239000006196 drop Substances 0.000 description 2
• 238000012377 drug delivery Methods 0.000 description 2
• 238000002651 drug therapy Methods 0.000 description 2
• 201000009028 early myoclonic encephalopathy Diseases 0.000 description 2
• 239000012636 effector Substances 0.000 description 2
• 210000001513 elbow Anatomy 0.000 description 2
• 230000005684 electric field Effects 0.000 description 2
• 238000005516 engineering process Methods 0.000 description 2
• 210000001353 entorhinal cortex Anatomy 0.000 description 2
• 208000028329 epileptic seizure Diseases 0.000 description 2
• 210000000981 epithelium Anatomy 0.000 description 2
• 230000005284 excitation Effects 0.000 description 2
• 231100000318 excitotoxic Toxicity 0.000 description 2
• 231100000063 excitotoxicity Toxicity 0.000 description 2
• 239000004060 excitotoxin Substances 0.000 description 2
• 239000012091 fetal bovine serum Substances 0.000 description 2
• 229960000449 flecainide Drugs 0.000 description 2
• 239000007850 fluorescent dye Substances 0.000 description 2
• 239000012634 fragment Substances 0.000 description 2
• 239000000499 gel Substances 0.000 description 2
• BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
• 239000011521 glass Substances 0.000 description 2
• 201000005442 glossopharyngeal neuralgia Diseases 0.000 description 2
• 239000001963 growth medium Substances 0.000 description 2
• 230000036541 health Effects 0.000 description 2
• 210000002064 heart cell Anatomy 0.000 description 2
• 125000005842 heteroatom Chemical group 0.000 description 2
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
• 238000012203 high throughput assay Methods 0.000 description 2
• 238000013537 high throughput screening Methods 0.000 description 2
• 210000001624 hip Anatomy 0.000 description 2
• 201000009939 hypertensive encephalopathy Diseases 0.000 description 2
• 208000003532 hypothyroidism Diseases 0.000 description 2
• 230000002989 hypothyroidism Effects 0.000 description 2
• 230000006872 improvement Effects 0.000 description 2
• 238000000338 in vitro Methods 0.000 description 2
• 238000000099 in vitro assay Methods 0.000 description 2
• 230000007574 infarction Effects 0.000 description 2
• 238000010255 intramuscular injection Methods 0.000 description 2
• 239000007927 intramuscular injection Substances 0.000 description 2
• 239000007928 intraperitoneal injection Substances 0.000 description 2
• 238000007913 intrathecal administration Methods 0.000 description 2
• 238000001990 intravenous administration Methods 0.000 description 2
• 230000002427 irreversible effect Effects 0.000 description 2
• 208000037906 ischaemic injury Diseases 0.000 description 2
• 210000003127 knee Anatomy 0.000 description 2
• 210000002414 leg Anatomy 0.000 description 2
• 239000007788 liquid Substances 0.000 description 2
• 238000011068 loading method Methods 0.000 description 2
• 230000004807 localization Effects 0.000 description 2
• 210000003141 lower extremity Anatomy 0.000 description 2
• 229920002521 macromolecule Polymers 0.000 description 2
• 210000004962 mammalian cell Anatomy 0.000 description 2
• 239000000463 material Substances 0.000 description 2
• 208000030159 metabolic disease Diseases 0.000 description 2
• 230000004060 metabolic process Effects 0.000 description 2
• 230000001394 metastastic effect Effects 0.000 description 2
• 206010061289 metastatic neoplasm Diseases 0.000 description 2
• 229960003404 mexiletine Drugs 0.000 description 2
• 210000003657 middle cerebral artery Anatomy 0.000 description 2
• 230000009456 molecular mechanism Effects 0.000 description 2
• 230000007659 motor function Effects 0.000 description 2
• 238000010172 mouse model Methods 0.000 description 2
• 201000000585 muscular atrophy Diseases 0.000 description 2
• 206010028417 myasthenia gravis Diseases 0.000 description 2
• 208000010125 myocardial infarction Diseases 0.000 description 2
• 230000008587 neuronal excitability Effects 0.000 description 2
• 230000003040 nociceptive effect Effects 0.000 description 2
• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
• 210000000287 oocyte Anatomy 0.000 description 2
• 230000010355 oscillation Effects 0.000 description 2
• VATYWCRQDJIRAI-UHFFFAOYSA-N p-aminobenzaldehyde Chemical compound NC1=CC=C(C=O)C=C1 VATYWCRQDJIRAI-UHFFFAOYSA-N 0.000 description 2
• 230000008052 pain pathway Effects 0.000 description 2
• 230000036961 partial effect Effects 0.000 description 2
• 230000004963 pathophysiological condition Effects 0.000 description 2
• 230000037361 pathway Effects 0.000 description 2
• 208000030062 persistent idiopathic facial pain Diseases 0.000 description 2
• 239000000546 pharmaceutical excipient Substances 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
• 239000010452 phosphate Substances 0.000 description 2
• 125000004437 phosphorous atom Chemical group 0.000 description 2
• 229910052698 phosphorus Inorganic materials 0.000 description 2
• 230000000649 photocoagulation Effects 0.000 description 2
• 238000002428 photodynamic therapy Methods 0.000 description 2
• 230000035479 physiological effects, processes and functions Effects 0.000 description 2
• 230000035790 physiological processes and functions Effects 0.000 description 2
• 239000004033 plastic Substances 0.000 description 2
• 229920003023 plastic Polymers 0.000 description 2
• 229920001983 poloxamer Polymers 0.000 description 2
• 229920000656 polylysine Polymers 0.000 description 2
• 239000013641 positive control Substances 0.000 description 2
• 239000011591 potassium Substances 0.000 description 2
• 229910052700 potassium Inorganic materials 0.000 description 2
• 239000000843 powder Substances 0.000 description 2
• 238000002360 preparation method Methods 0.000 description 2
• 239000003755 preservative agent Substances 0.000 description 2
• 108090000765 processed proteins & peptides Proteins 0.000 description 2
• 238000012545 processing Methods 0.000 description 2
• 201000002212 progressive supranuclear palsy Diseases 0.000 description 2
• 102000004169 proteins and genes Human genes 0.000 description 2
• 210000000449 purkinje cell Anatomy 0.000 description 2
• 210000002763 pyramidal cell Anatomy 0.000 description 2
• 150000003254 radicals Chemical class 0.000 description 2
• 108020003175 receptors Proteins 0.000 description 2
• 102000005962 receptors Human genes 0.000 description 2
• 238000011084 recovery Methods 0.000 description 2
• 230000003252 repetitive effect Effects 0.000 description 2
• 230000004264 retinal detachment Effects 0.000 description 2
• 208000032253 retinal ischemia Diseases 0.000 description 2
• 230000001020 rhythmical effect Effects 0.000 description 2
• 238000007423 screening assay Methods 0.000 description 2
• 238000003375 selectivity assay Methods 0.000 description 2
• 210000002832 shoulder Anatomy 0.000 description 2
• 230000011664 signaling Effects 0.000 description 2
• 239000011780 sodium chloride Substances 0.000 description 2
• 239000007787 solid Substances 0.000 description 2
• 239000012453 solvate Substances 0.000 description 2
• 208000020431 spinal cord injury Diseases 0.000 description 2
• 201000005671 spondyloarthropathy Diseases 0.000 description 2
• 230000008925 spontaneous activity Effects 0.000 description 2
• 239000011550 stock solution Substances 0.000 description 2
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
• 229960005322 streptomycin Drugs 0.000 description 2
• 239000000725 suspension Substances 0.000 description 2
• 230000000946 synaptic effect Effects 0.000 description 2
• 208000006379 syphilis Diseases 0.000 description 2
• 239000003826 tablet Substances 0.000 description 2
• 201000008914 temporal lobe epilepsy Diseases 0.000 description 2
• 230000000542 thalamic effect Effects 0.000 description 2
• 210000001103 thalamus Anatomy 0.000 description 2
• 150000003568 thioethers Chemical class 0.000 description 2
• UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
• 208000037816 tissue injury Diseases 0.000 description 2
• 229960002872 tocainide Drugs 0.000 description 2
• 238000013518 transcription Methods 0.000 description 2
• 230000035897 transcription Effects 0.000 description 2
• QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
• 230000001960 triggered effect Effects 0.000 description 2
• 201000008827 tuberculosis Diseases 0.000 description 2
• 229930195735 unsaturated hydrocarbon Natural products 0.000 description 2
• 208000009852 uremia Diseases 0.000 description 2
• 230000002861 ventricular Effects 0.000 description 2
• 230000004393 visual impairment Effects 0.000 description 2
• 239000000664 voltage gated sodium channel blocking agent Substances 0.000 description 2
• NFLGAXVYCFJBMK-RKDXNWHRSA-N (+)-isomenthone Natural products CC(C)[C@H]1CC[C@@H](C)CC1=O NFLGAXVYCFJBMK-RKDXNWHRSA-N 0.000 description 1
• GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
• JCIIKRHCWVHVFF-UHFFFAOYSA-N 1,2,4-thiadiazol-5-amine;hydrochloride Chemical compound Cl.NC1=NC=NS1 JCIIKRHCWVHVFF-UHFFFAOYSA-N 0.000 description 1
• CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
• ZWVHTXAYIKBMEE-UHFFFAOYSA-N 2-hydroxyacetophenone Chemical compound OCC(=O)C1=CC=CC=C1 ZWVHTXAYIKBMEE-UHFFFAOYSA-N 0.000 description 1
• TUIXVQYWFSEXHA-UHFFFAOYSA-N 2-phenyl-5-pyridin-4-yl-1,3,4-oxadiazole Chemical compound C1=CC=CC=C1C1=NN=C(C=2C=CN=CC=2)O1 TUIXVQYWFSEXHA-UHFFFAOYSA-N 0.000 description 1
• ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
• GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
• AJHPGXZOIAYYDW-UHFFFAOYSA-N 3-(2-cyanophenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NC(C(O)=O)CC1=CC=CC=C1C#N AJHPGXZOIAYYDW-UHFFFAOYSA-N 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
• ALKYHXVLJMQRLQ-UHFFFAOYSA-M 3-carboxynaphthalen-2-olate Chemical compound C1=CC=C2C=C(C([O-])=O)C(O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-M 0.000 description 1
• AGNFWIZBEATIAK-UHFFFAOYSA-N 4-phenylbutylamine Chemical compound NCCCCC1=CC=CC=C1 AGNFWIZBEATIAK-UHFFFAOYSA-N 0.000 description 1
• FGXZWMCBNMMYPL-UHFFFAOYSA-N 4-propoxybenzaldehyde Chemical compound CCCOC1=CC=C(C=O)C=C1 FGXZWMCBNMMYPL-UHFFFAOYSA-N 0.000 description 1
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
• 206010065040 AIDS dementia complex Diseases 0.000 description 1
• 102100028187 ATP-binding cassette sub-family C member 6 Human genes 0.000 description 1
• 108091006112 ATPases Proteins 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 208000004142 Acute Retinal Necrosis Syndrome Diseases 0.000 description 1
• 208000026872 Addison Disease Diseases 0.000 description 1
• 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
• 241001439211 Almeida Species 0.000 description 1
• 208000000044 Amnesia Diseases 0.000 description 1
• 229930183010 Amphotericin Natural products 0.000 description 1
• QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 1
• 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 1
• 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 1
• 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 1
• 206010002091 Anaesthesia Diseases 0.000 description 1
• 206010002329 Aneurysm Diseases 0.000 description 1
• 208000005598 Angioid Streaks Diseases 0.000 description 1
• 241001550224 Apha Species 0.000 description 1
• 206010002945 Aphakia Diseases 0.000 description 1
• 200000000007 Arterial disease Diseases 0.000 description 1
• 208000022211 Arteriovenous Malformations Diseases 0.000 description 1
• 208000006820 Arthralgia Diseases 0.000 description 1
• 206010003571 Astrocytoma Diseases 0.000 description 1
• 206010060971 Astrocytoma malignant Diseases 0.000 description 1
• 206010003591 Ataxia Diseases 0.000 description 1
• 206010003628 Atonic seizures Diseases 0.000 description 1
• 208000006373 Bell palsy Diseases 0.000 description 1
• 239000005711 Benzoic acid Substances 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
• 201000007795 Bietti crystalline corneoretinal dystrophy Diseases 0.000 description 1
• 208000019352 Blepharospasm-oromandibular dystonia syndrome Diseases 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 208000003174 Brain Neoplasms Diseases 0.000 description 1
• 208000014644 Brain disease Diseases 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
• 206010006542 Bulbar palsy Diseases 0.000 description 1
• 206010006784 Burning sensation Diseases 0.000 description 1
• 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
• 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
• NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
• RZZPDXZPRHQOCG-OJAKKHQRSA-N CDP-choline Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP([O-])(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-N 0.000 description 1
• 241000244203 Caenorhabditis elegans Species 0.000 description 1
• 101100479039 Caenorhabditis elegans aars-1 gene Proteins 0.000 description 1
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
• 235000002568 Capsicum frutescens Nutrition 0.000 description 1
• 239000004215 Carbon black (E152) Substances 0.000 description 1
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
• 206010048610 Cardiotoxicity Diseases 0.000 description 1
• 102000011727 Caspases Human genes 0.000 description 1
• 108010076667 Caspases Proteins 0.000 description 1
• 102000053642 Catalytic RNA Human genes 0.000 description 1
• 108090000994 Catalytic RNA Proteins 0.000 description 1
• 208000002177 Cataract Diseases 0.000 description 1
• 208000003163 Cavernous Hemangioma Diseases 0.000 description 1
• 208000003569 Central serous chorioretinopathy Diseases 0.000 description 1
• 241000238366 Cephalopoda Species 0.000 description 1
• 206010008027 Cerebellar atrophy Diseases 0.000 description 1
• 206010057854 Cerebral Toxoplasmosis Diseases 0.000 description 1
• 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 1
• 201000008992 Charcot-Marie-Tooth disease type 1B Diseases 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• 206010008748 Chorea Diseases 0.000 description 1
• 208000033825 Chorioretinal atrophy Diseases 0.000 description 1
• 206010070957 Choroidal haemangioma Diseases 0.000 description 1
• 235000001258 Cinchona calisaya Nutrition 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 1
• 206010009346 Clonus Diseases 0.000 description 1
• 206010053567 Coagulopathies Diseases 0.000 description 1
• 108020004635 Complementary DNA Proteins 0.000 description 1
• 206010010144 Completed suicide Diseases 0.000 description 1
• 208000033001 Complex partial seizures Diseases 0.000 description 1
• 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 1
• 206010010356 Congenital anomaly Diseases 0.000 description 1
• 206010010741 Conjunctivitis Diseases 0.000 description 1
• 208000034656 Contusions Diseases 0.000 description 1
• 206010011091 Coronary artery thrombosis Diseases 0.000 description 1
• 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
• 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
• 238000011765 DBA/2 mouse Methods 0.000 description 1
• 108020004414 DNA Proteins 0.000 description 1
• 206010053990 Dacryostenosis acquired Diseases 0.000 description 1
• 206010012335 Dependence Diseases 0.000 description 1
• 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
• 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
• 208000001654 Drug Resistant Epilepsy Diseases 0.000 description 1
• 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
• 238000001061 Dunnett's test Methods 0.000 description 1
• 208000005819 Dystonia Musculorum Deformans Diseases 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 208000019878 Eales disease Diseases 0.000 description 1
• 101000640022 Electrophorus electricus Sodium channel protein Proteins 0.000 description 1
• 208000005189 Embolism Diseases 0.000 description 1
• 208000032274 Encephalopathy Diseases 0.000 description 1
• 102000004190 Enzymes Human genes 0.000 description 1
• 108090000790 Enzymes Proteins 0.000 description 1
• 206010014967 Ependymoma Diseases 0.000 description 1
• 208000002877 Epileptic Syndromes Diseases 0.000 description 1
• 241000283073 Equus caballus Species 0.000 description 1
• 241000588724 Escherichia coli Species 0.000 description 1
• 206010015719 Exsanguination Diseases 0.000 description 1
• 208000029728 Eyelid disease Diseases 0.000 description 1
• 229940124602 FDA-approved drug Drugs 0.000 description 1
• 208000028506 Familial Exudative Vitreoretinopathies Diseases 0.000 description 1
• 208000024412 Friedreich ataxia Diseases 0.000 description 1
• 201000011240 Frontotemporal dementia Diseases 0.000 description 1
• 101150007682 Gabrg2 gene Proteins 0.000 description 1
• 206010017999 Gastrointestinal pain Diseases 0.000 description 1
• 206010064571 Gene mutation Diseases 0.000 description 1
• 208000003078 Generalized Epilepsy Diseases 0.000 description 1
• 208000000527 Germinoma Diseases 0.000 description 1
• 208000003736 Gerstmann-Straussler-Scheinker Disease Diseases 0.000 description 1
• 206010072075 Gerstmann-Straussler-Scheinker syndrome Diseases 0.000 description 1
• 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 1
• 206010018338 Glioma Diseases 0.000 description 1
• 229920001503 Glucan Polymers 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• 208000034308 Grand mal convulsion Diseases 0.000 description 1
• 208000003807 Graves Disease Diseases 0.000 description 1
• 208000015023 Graves' disease Diseases 0.000 description 1
• 108010078321 Guanylate Cyclase Proteins 0.000 description 1
• 102000014469 Guanylate cyclase Human genes 0.000 description 1
• 102100039334 HAUS augmin-like complex subunit 1 Human genes 0.000 description 1
• 208000002927 Hamartoma Diseases 0.000 description 1
• 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
• 208000032843 Hemorrhage Diseases 0.000 description 1
• 208000000903 Herpes simplex encephalitis Diseases 0.000 description 1
• 206010063491 Herpes zoster oticus Diseases 0.000 description 1
• 241000238631 Hexapoda Species 0.000 description 1
• 201000002563 Histoplasmosis Diseases 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101100177185 Homo sapiens HAUS1 gene Proteins 0.000 description 1
• 101001111338 Homo sapiens Neurofilament heavy polypeptide Proteins 0.000 description 1
• 101000684826 Homo sapiens Sodium channel protein type 2 subunit alpha Proteins 0.000 description 1
• 101000684820 Homo sapiens Sodium channel protein type 3 subunit alpha Proteins 0.000 description 1
• OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• 208000000386 Hypertensive Intracranial Hemorrhage Diseases 0.000 description 1
• 206010020880 Hypertrophy Diseases 0.000 description 1
• 208000013016 Hypoglycemia Diseases 0.000 description 1
• 206010058558 Hypoperfusion Diseases 0.000 description 1
• 208000026350 Inborn Genetic disease Diseases 0.000 description 1
• 206010022158 Injury to brachial plexus due to birth trauma Diseases 0.000 description 1
• 102000012411 Intermediate Filament Proteins Human genes 0.000 description 1
• 108010061998 Intermediate Filament Proteins Proteins 0.000 description 1
• 206010022557 Intermediate uveitis Diseases 0.000 description 1
• 208000010038 Ischemic Optic Neuropathy Diseases 0.000 description 1
• 241000235058 Komagataella pastoris Species 0.000 description 1
• PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
• 206010024229 Leprosy Diseases 0.000 description 1
• 208000009829 Lewy Body Disease Diseases 0.000 description 1
• 201000002832 Lewy body dementia Diseases 0.000 description 1
• 239000000232 Lipid Bilayer Substances 0.000 description 1
• 208000008930 Low Back Pain Diseases 0.000 description 1
• 208000016604 Lyme disease Diseases 0.000 description 1
• 206010025412 Macular dystrophy congenital Diseases 0.000 description 1
• 208000031471 Macular fibrosis Diseases 0.000 description 1
• 206010025415 Macular oedema Diseases 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 201000005190 Meige syndrome Diseases 0.000 description 1
• 201000009906 Meningitis Diseases 0.000 description 1
• NFLGAXVYCFJBMK-UHFFFAOYSA-N Menthone Chemical compound CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 description 1
• 206010027476 Metastases Diseases 0.000 description 1
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
• 208000009857 Microaneurysm Diseases 0.000 description 1
• 206010061296 Motor dysfunction Diseases 0.000 description 1
• 208000010164 Multifocal Choroiditis Diseases 0.000 description 1
• 208000002430 Multiple chemical sensitivity Diseases 0.000 description 1
• 208000008238 Muscle Spasticity Diseases 0.000 description 1
• 208000010428 Muscle Weakness Diseases 0.000 description 1
• 206010028289 Muscle atrophy Diseases 0.000 description 1
• 206010049565 Muscle fatigue Diseases 0.000 description 1
• 206010028347 Muscle twitching Diseases 0.000 description 1
• 206010028372 Muscular weakness Diseases 0.000 description 1
• 102000006386 Myelin Proteins Human genes 0.000 description 1
• 108010083674 Myelin Proteins Proteins 0.000 description 1
• 208000006123 Myiasis Diseases 0.000 description 1
• 208000002033 Myoclonus Diseases 0.000 description 1
• 150000001204 N-oxides Chemical class 0.000 description 1
• 229910017852 NH2NH2 Inorganic materials 0.000 description 1
• 229910002651 NO3 Inorganic materials 0.000 description 1
• 206010028813 Nausea Diseases 0.000 description 1
• 206010028851 Necrosis Diseases 0.000 description 1
• 206010065119 Necrotising herpetic retinopathy Diseases 0.000 description 1
• 101710165986 Negative regulator of transcription Proteins 0.000 description 1
• 206010029174 Nerve compression Diseases 0.000 description 1
• 206010056677 Nerve degeneration Diseases 0.000 description 1
• 206010029260 Neuroblastoma Diseases 0.000 description 1
• 208000007920 Neurogenic Inflammation Diseases 0.000 description 1
• 208000005890 Neuroma Diseases 0.000 description 1
• 206010029350 Neurotoxicity Diseases 0.000 description 1
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
• 102000006538 Nitric Oxide Synthase Type I Human genes 0.000 description 1
• 108010008858 Nitric Oxide Synthase Type I Proteins 0.000 description 1
• 108020004485 Nonsense Codon Proteins 0.000 description 1
• 108091028043 Nucleic acid sequence Proteins 0.000 description 1
• 206010069385 Ocular ischaemic syndrome Diseases 0.000 description 1
• 206010065700 Ocular sarcoidosis Diseases 0.000 description 1
• 208000003435 Optic Neuritis Diseases 0.000 description 1
• 206010030924 Optic ischaemic neuropathy Diseases 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 208000008558 Osteophyte Diseases 0.000 description 1
• 208000001132 Osteoporosis Diseases 0.000 description 1
• 208000012868 Overgrowth Diseases 0.000 description 1
• 206010065373 Papillophlebitis Diseases 0.000 description 1
• 206010033885 Paraparesis Diseases 0.000 description 1
• 208000027089 Parkinsonian disease Diseases 0.000 description 1
• 208000004788 Pars Planitis Diseases 0.000 description 1
• 208000037158 Partial Epilepsies Diseases 0.000 description 1
• 208000034247 Pattern dystrophy Diseases 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 229930182555 Penicillin Natural products 0.000 description 1
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 208000031845 Pernicious anaemia Diseases 0.000 description 1
• 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
• 208000024571 Pick disease Diseases 0.000 description 1
• 229920005372 Plexiglas® Polymers 0.000 description 1
• 241001417524 Pomacanthidae Species 0.000 description 1
• 102000004257 Potassium Channel Human genes 0.000 description 1
• 102000012412 Presenilin-1 Human genes 0.000 description 1
• 108010036933 Presenilin-1 Proteins 0.000 description 1
• 206010063664 Presumed ocular histoplasmosis syndrome Diseases 0.000 description 1
• 208000032319 Primary lateral sclerosis Diseases 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 208000033796 Pseudophakia Diseases 0.000 description 1
• 201000004613 Pseudoxanthoma elasticum Diseases 0.000 description 1
• 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 1
• 208000005587 Refsum Disease Diseases 0.000 description 1
• 208000033464 Reiter syndrome Diseases 0.000 description 1
• 208000008709 Retinal Telangiectasis Diseases 0.000 description 1
• 201000001949 Retinal Vasculitis Diseases 0.000 description 1
• 208000032430 Retinal dystrophy Diseases 0.000 description 1
• 208000032398 Retinal pigment epitheliopathy Diseases 0.000 description 1
• 206010038897 Retinal tear Diseases 0.000 description 1
• 241001338644 Retinia Species 0.000 description 1
• 206010038910 Retinitis Diseases 0.000 description 1
• 206010038915 Retinitis viral Diseases 0.000 description 1
• 201000000582 Retinoblastoma Diseases 0.000 description 1
• 206010038935 Retinopathy sickle cell Diseases 0.000 description 1
• 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
• 206010039491 Sarcoma Diseases 0.000 description 1
• 206010039705 Scleritis Diseases 0.000 description 1
• 241001247145 Sebastes goodei Species 0.000 description 1
• 206010039897 Sedation Diseases 0.000 description 1
• 206010039966 Senile dementia Diseases 0.000 description 1
• 208000014286 Serpiginous choroiditis Diseases 0.000 description 1
• 208000009106 Shy-Drager Syndrome Diseases 0.000 description 1
• 206010040703 Simple partial seizures Diseases 0.000 description 1
• 208000021386 Sjogren Syndrome Diseases 0.000 description 1
• 102100028910 Sodium channel protein type 1 subunit alpha Human genes 0.000 description 1
• 102100023150 Sodium channel protein type 2 subunit alpha Human genes 0.000 description 1
• 102100023720 Sodium channel protein type 3 subunit alpha Human genes 0.000 description 1
• 208000022758 Sorsby fundus dystrophy Diseases 0.000 description 1
• 208000002548 Spastic Paraparesis Diseases 0.000 description 1
• 208000032930 Spastic paraplegia Diseases 0.000 description 1
• 201000002661 Spondylitis Diseases 0.000 description 1
• 208000010040 Sprains and Strains Diseases 0.000 description 1
• 208000007107 Stomach Ulcer Diseases 0.000 description 1
• 208000004350 Strabismus Diseases 0.000 description 1
• 208000037132 Subdural Chronic Hematoma Diseases 0.000 description 1
• 208000002667 Subdural Hematoma Diseases 0.000 description 1
• 208000036038 Subretinal fibrosis Diseases 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• 241000282898 Sus scrofa Species 0.000 description 1
• 206010042742 Sympathetic ophthalmia Diseases 0.000 description 1
• 206010042953 Systemic sclerosis Diseases 0.000 description 1
• 229920002253 Tannate Polymers 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• 206010043189 Telangiectasia Diseases 0.000 description 1
• 208000009205 Tinnitus Diseases 0.000 description 1
• 208000026062 Tissue disease Diseases 0.000 description 1
• 208000000323 Tourette Syndrome Diseases 0.000 description 1
• 208000016620 Tourette disease Diseases 0.000 description 1
• 206010044221 Toxic encephalopathy Diseases 0.000 description 1
• 206010044269 Toxocariasis Diseases 0.000 description 1
• 206010052779 Transplant rejections Diseases 0.000 description 1
• 208000030886 Traumatic Brain injury Diseases 0.000 description 1
• 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
• 206010064996 Ulcerative keratitis Diseases 0.000 description 1
• 208000003443 Unconsciousness Diseases 0.000 description 1
• 206010046298 Upper motor neurone lesion Diseases 0.000 description 1
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
• 208000001445 Uveomeningoencephalitic Syndrome Diseases 0.000 description 1
• 208000036826 VIIth nerve paralysis Diseases 0.000 description 1
• 201000004810 Vascular dementia Diseases 0.000 description 1
• 206010047115 Vasculitis Diseases 0.000 description 1
• 208000034705 Vogt-Koyanagi-Harada syndrome Diseases 0.000 description 1
• 206010047700 Vomiting Diseases 0.000 description 1
• 206010052428 Wound Diseases 0.000 description 1
• 201000001408 X-linked juvenile retinoschisis 1 Diseases 0.000 description 1
• 208000017441 X-linked retinoschisis Diseases 0.000 description 1
• ABRVLXLNVJHDRQ-UHFFFAOYSA-N [2-pyridin-3-yl-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound FC(C1=CC(=CC(=N1)C=1C=NC=CC=1)CN)(F)F ABRVLXLNVJHDRQ-UHFFFAOYSA-N 0.000 description 1
• VEUACKUBDLVUAC-UHFFFAOYSA-N [Na].[Ca] Chemical group [Na].[Ca] VEUACKUBDLVUAC-UHFFFAOYSA-N 0.000 description 1
• 210000001015 abdomen Anatomy 0.000 description 1
• 208000003554 absence epilepsy Diseases 0.000 description 1
• 208000028311 absence seizure Diseases 0.000 description 1
• 239000003070 absorption delaying agent Substances 0.000 description 1
• 239000008351 acetate buffer Substances 0.000 description 1
• 229960004308 acetylcysteine Drugs 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 208000019672 acute posterior multifocal placoid pigment epitheliopathy Diseases 0.000 description 1
• 208000009956 adenocarcinoma Diseases 0.000 description 1
• 208000030597 adult Refsum disease Diseases 0.000 description 1
• 210000003766 afferent neuron Anatomy 0.000 description 1
• 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
• 150000001447 alkali salts Chemical class 0.000 description 1
• 125000005907 alkyl ester group Chemical group 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• 230000000172 allergic effect Effects 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• 230000001668 ameliorated effect Effects 0.000 description 1
• 108010016628 ameroid Proteins 0.000 description 1
• 229910021529 ammonia Inorganic materials 0.000 description 1
• 229940009444 amphotericin Drugs 0.000 description 1
• APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
• 238000002266 amputation Methods 0.000 description 1
• DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
• 230000037005 anaesthesia Effects 0.000 description 1
• 201000007058 anterior ischemic optic neuropathy Diseases 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000003574 anti-allodynic effect Effects 0.000 description 1
• 230000001773 anti-convulsant effect Effects 0.000 description 1
• 230000003502 anti-nociceptive effect Effects 0.000 description 1
• 230000000573 anti-seizure effect Effects 0.000 description 1
• 239000003429 antifungal agent Substances 0.000 description 1
• 229940121375 antifungal agent Drugs 0.000 description 1
• 239000000427 antigen Substances 0.000 description 1
• 108091007433 antigens Proteins 0.000 description 1
• 102000036639 antigens Human genes 0.000 description 1
• 230000001640 apoptogenic effect Effects 0.000 description 1
• 239000012736 aqueous medium Substances 0.000 description 1
• 150000004982 aromatic amines Chemical class 0.000 description 1
• 210000002565 arteriole Anatomy 0.000 description 1
• 230000005744 arteriovenous malformation Effects 0.000 description 1
• 230000001174 ascending effect Effects 0.000 description 1
• 201000009310 astigmatism Diseases 0.000 description 1
• 208000010668 atopic eczema Diseases 0.000 description 1
• 210000001992 atrioventricular node Anatomy 0.000 description 1
• 230000002238 attenuated effect Effects 0.000 description 1
• 230000004979 auditory behavior Effects 0.000 description 1
• 210000000467 autonomic pathway Anatomy 0.000 description 1
• OISFUZRUIGGTSD-LJTMIZJLSA-N azane;(2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound N.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO OISFUZRUIGGTSD-LJTMIZJLSA-N 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• 229960000686 benzalkonium chloride Drugs 0.000 description 1
• 229940077388 benzenesulfonate Drugs 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
• 235000010233 benzoic acid Nutrition 0.000 description 1
• AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
• CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
• 229940064804 betadine Drugs 0.000 description 1
• 125000005841 biaryl group Chemical group 0.000 description 1
• 230000001588 bifunctional effect Effects 0.000 description 1
• 230000002146 bilateral effect Effects 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 206010072959 birdshot chorioretinopathy Diseases 0.000 description 1
• 206010005159 blepharospasm Diseases 0.000 description 1
• 230000000744 blepharospasm Effects 0.000 description 1
• 230000008499 blood brain barrier function Effects 0.000 description 1
• 208000015294 blood coagulation disease Diseases 0.000 description 1
• 210000001218 blood-brain barrier Anatomy 0.000 description 1
• 210000001185 bone marrow Anatomy 0.000 description 1
• 239000005388 borosilicate glass Substances 0.000 description 1
• 201000006431 brachial plexus neuropathy Diseases 0.000 description 1
• 208000009973 brain hypoxia - ischemia Diseases 0.000 description 1
• 201000005845 branch retinal artery occlusion Diseases 0.000 description 1
• 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
• 239000007975 buffered saline Substances 0.000 description 1
• 239000004067 bulking agent Substances 0.000 description 1
• KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
• 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
• 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
• CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
• 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
• 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
• 239000001110 calcium chloride Substances 0.000 description 1
• 235000011148 calcium chloride Nutrition 0.000 description 1
• 229910001628 calcium chloride Inorganic materials 0.000 description 1
• 230000009460 calcium influx Effects 0.000 description 1
• 230000003185 calcium uptake Effects 0.000 description 1
• MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
• 229960002504 capsaicin Drugs 0.000 description 1
• 235000017663 capsaicin Nutrition 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
• 210000004413 cardiac myocyte Anatomy 0.000 description 1
• 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
• 231100000259 cardiotoxicity Toxicity 0.000 description 1
• 210000000748 cardiovascular system Anatomy 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 230000003197 catalytic effect Effects 0.000 description 1
• 238000000423 cell based assay Methods 0.000 description 1
• 239000006143 cell culture medium Substances 0.000 description 1
• 230000005779 cell damage Effects 0.000 description 1
• 208000037887 cell injury Diseases 0.000 description 1
• 208000015114 central nervous system disease Diseases 0.000 description 1
• 239000000919 ceramic Substances 0.000 description 1
• 201000007335 cerebellar astrocytoma Diseases 0.000 description 1
• 201000007990 cerebellar medulloblastoma Diseases 0.000 description 1
• 210000003710 cerebral cortex Anatomy 0.000 description 1
• 208000026106 cerebrovascular disease Diseases 0.000 description 1
• 210000004720 cerebrum Anatomy 0.000 description 1
• 229940125400 channel inhibitor Drugs 0.000 description 1
• 125000001309 chloro group Chemical group Cl* 0.000 description 1
• 229960004926 chlorobutanol Drugs 0.000 description 1
• 208000012601 choreatic disease Diseases 0.000 description 1
• 210000003161 choroid Anatomy 0.000 description 1
• 208000027129 choroid disease Diseases 0.000 description 1
• 230000006020 chronic inflammation Effects 0.000 description 1
• 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
• 208000022371 chronic pain syndrome Diseases 0.000 description 1
• 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
• 230000001886 ciliary effect Effects 0.000 description 1
• LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
• 210000000275 circle of willis Anatomy 0.000 description 1
• 230000004087 circulation Effects 0.000 description 1
• 239000007979 citrate buffer Substances 0.000 description 1
• 235000015165 citric acid Nutrition 0.000 description 1
• 229940090805 clavulanate Drugs 0.000 description 1
• HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 1
• 230000008045 co-localization Effects 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 230000001149 cognitive effect Effects 0.000 description 1
• 239000002299 complementary DNA Substances 0.000 description 1
• 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 1
• 230000001010 compromised effect Effects 0.000 description 1
• 201000008615 cone dystrophy Diseases 0.000 description 1
• 208000006623 congenital stationary night blindness Diseases 0.000 description 1
• 210000002808 connective tissue Anatomy 0.000 description 1
• 230000008602 contraction Effects 0.000 description 1
• 239000000599 controlled substance Substances 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 230000009519 contusion Effects 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 210000004087 cornea Anatomy 0.000 description 1
• 208000021921 corneal disease Diseases 0.000 description 1
• 201000007717 corneal ulcer Diseases 0.000 description 1
• 208000029078 coronary artery disease Diseases 0.000 description 1
• 208000002528 coronary thrombosis Diseases 0.000 description 1
• 210000004351 coronary vessel Anatomy 0.000 description 1
• 208000013044 corticobasal degeneration disease Diseases 0.000 description 1
• IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
• 229960000258 corticotropin Drugs 0.000 description 1
• 230000005574 cross-species transmission Effects 0.000 description 1
• 125000000753 cycloalkyl group Chemical group 0.000 description 1
• 230000001086 cytosolic effect Effects 0.000 description 1
• 231100000433 cytotoxic Toxicity 0.000 description 1
• 230000001472 cytotoxic effect Effects 0.000 description 1
• 230000000254 damaging effect Effects 0.000 description 1
• 238000007405 data analysis Methods 0.000 description 1
• 230000003412 degenerative effect Effects 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 239000008367 deionised water Substances 0.000 description 1
• 229910021641 deionized water Inorganic materials 0.000 description 1
• 230000001934 delay Effects 0.000 description 1
• 238000012217 deletion Methods 0.000 description 1
• 230000037430 deletion Effects 0.000 description 1
• 210000001787 dendrite Anatomy 0.000 description 1
• 201000001981 dermatomyositis Diseases 0.000 description 1
• 208000033679 diabetic kidney disease Diseases 0.000 description 1
• 125000005265 dialkylamine group Chemical group 0.000 description 1
• ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• SPCNPOWOBZQWJK-UHFFFAOYSA-N dimethoxy-(2-propan-2-ylsulfanylethylsulfanyl)-sulfanylidene-$l^{5}-phosphane Chemical compound COP(=S)(OC)SCCSC(C)C SPCNPOWOBZQWJK-UHFFFAOYSA-N 0.000 description 1
• 239000001177 diphosphate Substances 0.000 description 1
• XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
• 235000011180 diphosphates Nutrition 0.000 description 1
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
• 238000007599 discharging Methods 0.000 description 1
• 208000016097 disease of metabolism Diseases 0.000 description 1
• 239000002612 dispersion medium Substances 0.000 description 1
• 208000002173 dizziness Diseases 0.000 description 1
• POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
• 238000011833 dog model Methods 0.000 description 1
• 210000005064 dopaminergic neuron Anatomy 0.000 description 1
• 230000002222 downregulating effect Effects 0.000 description 1
• 230000003828 downregulation Effects 0.000 description 1
• 238000001647 drug administration Methods 0.000 description 1
• 238000007876 drug discovery Methods 0.000 description 1
• 208000000718 duodenal ulcer Diseases 0.000 description 1
• 230000004064 dysfunction Effects 0.000 description 1
• 230000008482 dysregulation Effects 0.000 description 1
• 238000013399 early diagnosis Methods 0.000 description 1
• 208000016570 early-onset generalized limb-onset dystonia Diseases 0.000 description 1
• 229940009662 edetate Drugs 0.000 description 1
• 230000002828 effect on organs or tissue Effects 0.000 description 1
• 238000001962 electrophoresis Methods 0.000 description 1
• 230000007831 electrophysiology Effects 0.000 description 1
• 238000002001 electrophysiology Methods 0.000 description 1
• 230000003073 embolic effect Effects 0.000 description 1
• 229950005627 embonate Drugs 0.000 description 1
• 210000002257 embryonic structure Anatomy 0.000 description 1
• 238000000295 emission spectrum Methods 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 230000001804 emulsifying effect Effects 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 206010014801 endophthalmitis Diseases 0.000 description 1
• 239000000066 endothelium dependent relaxing factor Substances 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
• 229960001123 epoprostenol Drugs 0.000 description 1
• 239000003797 essential amino acid Substances 0.000 description 1
• 235000020776 essential amino acid Nutrition 0.000 description 1
• 201000006517 essential tremor Diseases 0.000 description 1
• 230000032050 esterification Effects 0.000 description 1
• 238000005886 esterification reaction Methods 0.000 description 1
• 229950000206 estolate Drugs 0.000 description 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
• 150000002170 ethers Chemical class 0.000 description 1
• AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 230000000763 evoking effect Effects 0.000 description 1
• 201000004356 excessive tearing Diseases 0.000 description 1
• 238000000695 excitation spectrum Methods 0.000 description 1
• 230000001747 exhibiting effect Effects 0.000 description 1
• 201000010934 exostosis Diseases 0.000 description 1
• 238000013401 experimental design Methods 0.000 description 1
• 239000000284 extract Substances 0.000 description 1
• 201000006902 exudative vitreoretinopathy Diseases 0.000 description 1
• 210000000744 eyelid Anatomy 0.000 description 1
• 230000003176 fibrotic effect Effects 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 239000003269 fluorescent indicator Substances 0.000 description 1
• 235000013305 food Nutrition 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 210000000245 forearm Anatomy 0.000 description 1
• 239000012458 free base Substances 0.000 description 1
• 229940050411 fumarate Drugs 0.000 description 1
• 239000001530 fumaric acid Substances 0.000 description 1
• 125000000524 functional group Chemical group 0.000 description 1
• 230000002538 fungal effect Effects 0.000 description 1
• 125000002541 furyl group Chemical group 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 230000030279 gene silencing Effects 0.000 description 1
• 238000012226 gene silencing method Methods 0.000 description 1
• 208000014204 generalized epilepsy with febrile seizures plus 2 Diseases 0.000 description 1
• 230000009395 genetic defect Effects 0.000 description 1
• 208000016361 genetic disease Diseases 0.000 description 1
• 201000011349 geniculate herpes zoster Diseases 0.000 description 1
• 238000011556 gerbil model Methods 0.000 description 1
• 229960001731 gluceptate Drugs 0.000 description 1
• KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
• 229940050410 gluconate Drugs 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 230000007946 glucose deprivation Effects 0.000 description 1
• 229940049906 glutamate Drugs 0.000 description 1
• 235000011187 glycerol Nutrition 0.000 description 1
• 210000003128 head Anatomy 0.000 description 1
• 230000004217 heart function Effects 0.000 description 1
• 210000005003 heart tissue Anatomy 0.000 description 1
• 208000034737 hemoglobinopathy Diseases 0.000 description 1
• 230000023597 hemostasis Effects 0.000 description 1
• 208000027700 hepatic dysfunction Diseases 0.000 description 1
• IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
• 238000012188 high-throughput screening assay Methods 0.000 description 1
• 210000004295 hippocampal neuron Anatomy 0.000 description 1
• 210000001320 hippocampus Anatomy 0.000 description 1
• 230000004694 hippocampus damage Effects 0.000 description 1
• XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
• 150000004677 hydrates Chemical class 0.000 description 1
• 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 1
• 229930195733 hydrocarbon Natural products 0.000 description 1
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
• 230000009610 hypersensitivity Effects 0.000 description 1
• 230000001631 hypertensive effect Effects 0.000 description 1
• 230000001969 hypertrophic effect Effects 0.000 description 1
• 201000001993 idiopathic generalized epilepsy Diseases 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• 125000002883 imidazolyl group Chemical group 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• 238000010874 in vitro model Methods 0.000 description 1
• 238000005462 in vivo assay Methods 0.000 description 1
• 239000005414 inactive ingredient Substances 0.000 description 1
• 230000001939 inductive effect Effects 0.000 description 1
• 239000012678 infectious agent Substances 0.000 description 1
• 230000002458 infectious effect Effects 0.000 description 1
• 230000000266 injurious effect Effects 0.000 description 1
• 230000030214 innervation Effects 0.000 description 1
• 238000007689 inspection Methods 0.000 description 1
• 230000035990 intercellular signaling Effects 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 230000004410 intraocular pressure Effects 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• 239000000644 isotonic solution Substances 0.000 description 1
• 239000007951 isotonicity adjuster Substances 0.000 description 1
• 230000009191 jumping Effects 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 238000011005 laboratory method Methods 0.000 description 1
• 208000016747 lacrimal apparatus disease Diseases 0.000 description 1
• 208000000617 lacrimal duct obstruction Diseases 0.000 description 1
• 229940001447 lactate Drugs 0.000 description 1
• 229940099584 lactobionate Drugs 0.000 description 1
• JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
• 238000013532 laser treatment Methods 0.000 description 1
• 201000010901 lateral sclerosis Diseases 0.000 description 1
• 229940070765 laurate Drugs 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• 201000002364 leukopenia Diseases 0.000 description 1
• 231100001022 leukopenia Toxicity 0.000 description 1
• 238000011542 limb amputation Methods 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 239000003589 local anesthetic agent Substances 0.000 description 1
• 229960005015 local anesthetics Drugs 0.000 description 1
• 230000005923 long-lasting effect Effects 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 231100000863 loss of memory Toxicity 0.000 description 1
• 231100000864 loss of vision Toxicity 0.000 description 1
• 208000018769 loss of vision Diseases 0.000 description 1
• 210000004705 lumbosacral region Anatomy 0.000 description 1
• 208000019420 lymphoid neoplasm Diseases 0.000 description 1
• 208000029233 macular holes Diseases 0.000 description 1
• 201000010230 macular retinal edema Diseases 0.000 description 1
• 229910001629 magnesium chloride Inorganic materials 0.000 description 1
• 159000000003 magnesium salts Chemical class 0.000 description 1
• 229940049920 malate Drugs 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
• IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 238000004519 manufacturing process Methods 0.000 description 1
• 108010082117 matrigel Proteins 0.000 description 1
• 206010027191 meningioma Diseases 0.000 description 1
• 230000003340 mental effect Effects 0.000 description 1
• 229930007503 menthone Natural products 0.000 description 1
• 230000006371 metabolic abnormality Effects 0.000 description 1
• 230000006609 metabolic stress Effects 0.000 description 1
• 230000009401 metastasis Effects 0.000 description 1
• 229940102396 methyl bromide Drugs 0.000 description 1
• LRMHVVPPGGOAJQ-UHFFFAOYSA-N methyl nitrate Chemical compound CO[N+]([O-])=O LRMHVVPPGGOAJQ-UHFFFAOYSA-N 0.000 description 1
• JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
• 230000027829 mitochondrial depolarization Effects 0.000 description 1
• 230000004898 mitochondrial function Effects 0.000 description 1
• 238000010369 molecular cloning Methods 0.000 description 1
• 230000020763 muscle atrophy Effects 0.000 description 1
• 230000004118 muscle contraction Effects 0.000 description 1
• 230000003387 muscular Effects 0.000 description 1
• 210000005012 myelin Anatomy 0.000 description 1
• 210000004165 myocardium Anatomy 0.000 description 1
• 210000000107 myocyte Anatomy 0.000 description 1
• 208000001491 myopia Diseases 0.000 description 1
• 230000004379 myopia Effects 0.000 description 1
• 239000004081 narcotic agent Substances 0.000 description 1
• 239000003887 narcotic antagonist Substances 0.000 description 1
• 230000003533 narcotic effect Effects 0.000 description 1
• 230000008693 nausea Effects 0.000 description 1
• 210000003739 neck Anatomy 0.000 description 1
• 230000017074 necrotic cell death Effects 0.000 description 1
• 239000013642 negative control Substances 0.000 description 1
• 230000001423 neocortical effect Effects 0.000 description 1
• 230000001613 neoplastic effect Effects 0.000 description 1
• 208000019382 nerve compression syndrome Diseases 0.000 description 1
• 210000004126 nerve fiber Anatomy 0.000 description 1
• 230000007426 neuronal cell dysfunction Effects 0.000 description 1
• 230000003955 neuronal function Effects 0.000 description 1
• 230000007171 neuropathology Effects 0.000 description 1
• 230000004112 neuroprotection Effects 0.000 description 1
• 201000002165 neuroretinitis Diseases 0.000 description 1
• 231100000189 neurotoxic Toxicity 0.000 description 1
• 230000002887 neurotoxic effect Effects 0.000 description 1
• 230000007135 neurotoxicity Effects 0.000 description 1
• 231100000228 neurotoxicity Toxicity 0.000 description 1
• 239000002858 neurotransmitter agent Substances 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 239000002840 nitric oxide donor Substances 0.000 description 1
• 230000010417 nitric oxide pathway Effects 0.000 description 1
• 210000000929 nociceptor Anatomy 0.000 description 1
• 108091008700 nociceptors Proteins 0.000 description 1
• 229940121367 non-opioid analgesics Drugs 0.000 description 1
• 230000037434 nonsense mutation Effects 0.000 description 1
• 230000001473 noxious effect Effects 0.000 description 1
• 235000015097 nutrients Nutrition 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• 208000008940 ocular tuberculosis Diseases 0.000 description 1
• 229940049964 oleate Drugs 0.000 description 1
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
• 208000031237 olivopontocerebellar atrophy Diseases 0.000 description 1
• 206010030875 ophthalmoplegia Diseases 0.000 description 1
• 229940127240 opiate Drugs 0.000 description 1
• 239000000014 opioid analgesic Substances 0.000 description 1
• 229940005483 opioid analgesics Drugs 0.000 description 1
• 229940124636 opioid drug Drugs 0.000 description 1
• 239000013110 organic ligand Substances 0.000 description 1
• 239000003960 organic solvent Substances 0.000 description 1
• 230000003534 oscillatory effect Effects 0.000 description 1
• 208000008798 osteoma Diseases 0.000 description 1
• AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
• 230000001590 oxidative effect Effects 0.000 description 1
• 230000036542 oxidative stress Effects 0.000 description 1
• 125000005430 oxychloro group Chemical group 0.000 description 1
• 230000000661 pacemaking effect Effects 0.000 description 1
• 230000008058 pain sensation Effects 0.000 description 1
• 229940124707 pain therapeutics Drugs 0.000 description 1
• 229940014662 pantothenate Drugs 0.000 description 1
• 208000002593 pantothenate kinase-associated neurodegeneration Diseases 0.000 description 1
• 235000019161 pantothenic acid Nutrition 0.000 description 1
• 239000011713 pantothenic acid Substances 0.000 description 1
• 208000035824 paresthesia Diseases 0.000 description 1
• 238000005192 partition Methods 0.000 description 1
• 230000032696 parturition Effects 0.000 description 1
• 231100000915 pathological change Toxicity 0.000 description 1
• 230000036285 pathological change Effects 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 239000008188 pellet Substances 0.000 description 1
• 229940049954 penicillin Drugs 0.000 description 1
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
• 239000000816 peptidomimetic Substances 0.000 description 1
• 230000000737 periodic effect Effects 0.000 description 1
• 230000000505 pernicious effect Effects 0.000 description 1
• 229940124531 pharmaceutical excipient Drugs 0.000 description 1
• 229940096826 phenylmercuric acetate Drugs 0.000 description 1
• PDTFCHSETJBPTR-UHFFFAOYSA-N phenylmercuric nitrate Chemical compound [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 description 1
• RGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical compound CCN(CC)C(=O)C(\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 1
• 239000008363 phosphate buffer Substances 0.000 description 1
• 239000002953 phosphate buffered saline Substances 0.000 description 1
• 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
• 150000003904 phospholipids Chemical class 0.000 description 1
• 238000000554 physical therapy Methods 0.000 description 1
• 239000000049 pigment Substances 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 230000036470 plasma concentration Effects 0.000 description 1
• 239000013600 plasmid vector Substances 0.000 description 1
• 231100000572 poisoning Toxicity 0.000 description 1
• 230000000607 poisoning effect Effects 0.000 description 1
• 239000004926 polymethyl methacrylate Substances 0.000 description 1
• 229920001184 polypeptide Polymers 0.000 description 1
• 239000011148 porous material Substances 0.000 description 1
• 201000004849 posterior scleritis Diseases 0.000 description 1
• 201000002267 posterior uveal melanoma Diseases 0.000 description 1
• 108020001213 potassium channel Proteins 0.000 description 1
• 239000001103 potassium chloride Substances 0.000 description 1
• 235000011164 potassium chloride Nutrition 0.000 description 1
• 229910001414 potassium ion Inorganic materials 0.000 description 1
• 159000000001 potassium salts Chemical class 0.000 description 1
• 201000010041 presbyopia Diseases 0.000 description 1
• 210000000063 presynaptic terminal Anatomy 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 210000002248 primary sensory neuron Anatomy 0.000 description 1
• 102000004196 processed proteins & peptides Human genes 0.000 description 1
• 229940002612 prodrug Drugs 0.000 description 1
• 239000000651 prodrug Substances 0.000 description 1
• 201000002241 progressive bulbar palsy Diseases 0.000 description 1
• 201000008752 progressive muscular atrophy Diseases 0.000 description 1
• 208000026526 progressive weakness Diseases 0.000 description 1
• 210000001236 prokaryotic cell Anatomy 0.000 description 1
• 201000007914 proliferative diabetic retinopathy Diseases 0.000 description 1
• 230000001902 propagating effect Effects 0.000 description 1
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 230000001681 protective effect Effects 0.000 description 1
• 208000023558 pseudoxanthoma elasticum (inherited or acquired) Diseases 0.000 description 1
• 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
• 208000034503 punctate inner choroidopathy Diseases 0.000 description 1
• 208000022749 pupil disease Diseases 0.000 description 1
• 210000003742 purkinje fiber Anatomy 0.000 description 1
• 125000003373 pyrazinyl group Chemical group 0.000 description 1
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
• 125000004076 pyridyl group Chemical group 0.000 description 1
• 125000000714 pyrimidinyl group Chemical group 0.000 description 1
• 125000000168 pyrrolyl group Chemical group 0.000 description 1
• 238000000275 quality assurance Methods 0.000 description 1
• 238000003908 quality control method Methods 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
• 229960000948 quinine Drugs 0.000 description 1
• 125000001567 quinoxalinyl group Chemical class N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
• 238000011555 rabbit model Methods 0.000 description 1
• 238000001959 radiotherapy Methods 0.000 description 1
• 208000002574 reactive arthritis Diseases 0.000 description 1
• 238000003259 recombinant expression Methods 0.000 description 1
• 238000004064 recycling Methods 0.000 description 1
• 208000000029 referred pain Diseases 0.000 description 1
• 208000014733 refractive error Diseases 0.000 description 1
• 230000000241 respiratory effect Effects 0.000 description 1
• 210000002345 respiratory system Anatomy 0.000 description 1
• 230000036390 resting membrane potential Effects 0.000 description 1
• 230000004283 retinal dysfunction Effects 0.000 description 1
• 210000003994 retinal ganglion cell Anatomy 0.000 description 1
• 201000007714 retinoschisis Diseases 0.000 description 1
• 108091092562 ribozyme Proteins 0.000 description 1
• 229940125526 sGC activator Drugs 0.000 description 1
• YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
• 229960001860 salicylate Drugs 0.000 description 1
• 229920006395 saturated elastomer Polymers 0.000 description 1
• 210000003786 sclera Anatomy 0.000 description 1
• 150000003335 secondary amines Chemical class 0.000 description 1
• 230000036280 sedation Effects 0.000 description 1
• 230000035807 sensation Effects 0.000 description 1
• 230000035939 shock Effects 0.000 description 1
• 210000001013 sinoatrial node Anatomy 0.000 description 1
• 150000003384 small molecules Chemical group 0.000 description 1
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
• 229940126121 sodium channel inhibitor Drugs 0.000 description 1
• HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
• HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 1
• 229940001584 sodium metabisulfite Drugs 0.000 description 1
• 235000010262 sodium metabisulphite Nutrition 0.000 description 1
• AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
• 229940001474 sodium thiosulfate Drugs 0.000 description 1
• 235000019345 sodium thiosulphate Nutrition 0.000 description 1
• 208000018198 spasticity Diseases 0.000 description 1
• 238000001228 spectrum Methods 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 208000005809 status epilepticus Diseases 0.000 description 1
• 239000008174 sterile solution Substances 0.000 description 1
• 230000004960 subcellular localization Effects 0.000 description 1
• 238000010254 subcutaneous injection Methods 0.000 description 1
• 239000007929 subcutaneous injection Substances 0.000 description 1
• 201000009032 substance abuse Diseases 0.000 description 1
• 231100000736 substance abuse Toxicity 0.000 description 1
• 208000011117 substance-related disease Diseases 0.000 description 1
• 210000003523 substantia nigra Anatomy 0.000 description 1
• 238000006467 substitution reaction Methods 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
• 229940124530 sulfonamide Drugs 0.000 description 1
• 150000003456 sulfonamides Chemical class 0.000 description 1
• 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 230000008961 swelling Effects 0.000 description 1
• 230000002194 synthesizing effect Effects 0.000 description 1
• 238000010189 synthetic method Methods 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 238000007910 systemic administration Methods 0.000 description 1
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 229940095064 tartrate Drugs 0.000 description 1
• 208000009056 telangiectasis Diseases 0.000 description 1
• 230000002123 temporal effect Effects 0.000 description 1
• 229950002757 teoclate Drugs 0.000 description 1
• 229940126585 therapeutic drug Drugs 0.000 description 1
• RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
• 229940033663 thimerosal Drugs 0.000 description 1
• 150000003573 thiols Chemical class 0.000 description 1
• QIQITDHWZYEEPA-UHFFFAOYSA-N thiophene-2-carbonyl chloride Chemical compound ClC(=O)C1=CC=CS1 QIQITDHWZYEEPA-UHFFFAOYSA-N 0.000 description 1
• 210000000115 thoracic cavity Anatomy 0.000 description 1
• 231100000886 tinnitus Toxicity 0.000 description 1
• 230000017423 tissue regeneration Effects 0.000 description 1
• 210000003371 toe Anatomy 0.000 description 1
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
• 230000036977 tonic contraction Effects 0.000 description 1
• 208000028325 tonic-clonic seizure Diseases 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 201000001340 torsion dystonia 1 Diseases 0.000 description 1
• 230000002103 transcriptional effect Effects 0.000 description 1
• 230000007704 transition Effects 0.000 description 1
• 238000013519 translation Methods 0.000 description 1
• 230000009529 traumatic brain injury Effects 0.000 description 1
• 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
• 125000004953 trihalomethyl group Chemical group 0.000 description 1
• 210000005239 tubule Anatomy 0.000 description 1
• 230000002476 tumorcidal effect Effects 0.000 description 1
• 210000001364 upper extremity Anatomy 0.000 description 1
• 210000000689 upper leg Anatomy 0.000 description 1
• 229940070710 valerate Drugs 0.000 description 1
• NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
• 230000003074 vasoproliferative effect Effects 0.000 description 1
• 239000013598 vector Substances 0.000 description 1
• 208000003663 ventricular fibrillation Diseases 0.000 description 1
• 239000013603 viral vector Substances 0.000 description 1
• 230000009278 visceral effect Effects 0.000 description 1
• 208000029257 vision disease Diseases 0.000 description 1
• 230000000007 visual effect Effects 0.000 description 1
• 201000007790 vitelliform macular dystrophy Diseases 0.000 description 1
• 108040002416 voltage-gated sodium channel activity proteins Proteins 0.000 description 1
• 102000008538 voltage-gated sodium channel activity proteins Human genes 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• 210000005253 yeast cell Anatomy 0.000 description 1